<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01976182</url>
  </required_header>
  <id_info>
    <org_study_id>LGL</org_study_id>
    <nct_id>NCT01976182</nct_id>
  </id_info>
  <brief_title>Prospective, Multicentric, Phase II Randomized Controlled Trial on Two Parallel Groups Comparing the Efficacy of Two Immunosuppressive Drugs (Methotrexate, Cyclophosphamide) in Large Granular Lymphocytes Leukemia</brief_title>
  <acronym>LGL</acronym>
  <official_title>Prospective, Sequential Multiple Assignment, Multicentric, Phase II Randomized Controlled Trial on Two Parallel Groups Comparing the Efficacy of Two Immunosuppressive Drugs (Methotrexate, Cyclophosphamide) in Large Granular Lymphocytes Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      LGL leukemia represents a rare subtype of chronic T or NK lymphoproliferative disorders. It&#xD;
      is an indolent disease, the main hematological or autoimmune complications lead to a&#xD;
      treatment in more than 60% of patients.&#xD;
&#xD;
      Investigators set up at the University Hospital of Rennes, a database of more than 300&#xD;
      patients with LGL leukemia from major French services that support this disease, and&#xD;
      published in 2010 the largest series of patients in the world (n = 229). However, the limited&#xD;
      heterogeneity and retrospective data collected, as all previously released, makes it&#xD;
      difficult the proposal of consensual treatment options. If first and second line treatments&#xD;
      are based on the use of immunosuppression with methotrexate, cyclophosphamide, or cyclosporin&#xD;
      A, no molecule has proven superiority over others. Methotrexate and cyclophosphamide are&#xD;
      mainly used in the first line. Invetigators just have in the literature data on about 100&#xD;
      patients treated with either of these drugs. Combining the results of our series with those&#xD;
      in the literature, invetigators estimate the respective overall response rate (RG) and&#xD;
      complete response rate (CR) in 55% and 30% for methotrexate, and 60% and 50% for&#xD;
      cyclophosphamide.&#xD;
&#xD;
      Thus, there are four objective in this study :&#xD;
&#xD;
        1. to compare the respective efficacies of methotrexate and cyclophosphamide when&#xD;
           administered as first-line therapies in patients suffering from T/NK LGL leukemia with&#xD;
           severe neutropenia or neutropenia associated with infections, and/or anemia requiring&#xD;
           transfusions, and/or auto-immune associated disease&#xD;
&#xD;
        2. to evaluate the percentage of patients refractory to methotrexate or cyclophosphamide&#xD;
           for which a second line treatment is efficacious&#xD;
&#xD;
        3. to explore, in case of non-response to the first-line therapy, the efficacy of&#xD;
           ciclosporine A, the comparison being performed with the treatment which was not&#xD;
           administered in the first-line therapy&#xD;
&#xD;
        4. to evaluate the response rate according to the phenotypic subtype of LGL leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Large Granular Lymphocyte (LGL) leukemia is a clonal disorder involving tissue invasion of&#xD;
      marrow, spleen and liver. Clinical presentation is dominated by recurrent infections&#xD;
      associated with neutropenia, anemia, splenomegaly, and auto-immune diseases, particularly&#xD;
      rheumatoid arthritis. Both T cell and NK cell subtypes of LGL leukemia are indolent disease&#xD;
      and considered as a chronic illness and lead to a treatment in more than 60% of patients.&#xD;
&#xD;
      LGL leukemia displays a chronic clinical course. Recommendations regarding therapy are&#xD;
      similar for both subtypes. Indications for treatment include 1) severe neutropenia (ANC &lt;500&#xD;
      mm3); 2) neutropenia (ANC &lt;1500mm3) with symptomatic recurrent infections; 3) symptomatic or&#xD;
      transfusion-dependent anemia and 4) associated autoimmune conditions requiring therapy, most&#xD;
      often rheumatoid arthritis.&#xD;
&#xD;
      There is no standard treatment for patients with LGL leukemia. The numerous case reports&#xD;
      published do not provide a consensus for a particular treatment. All the six largest series&#xD;
      published in the literature so far (collecting data on more than 40 patients) are&#xD;
      retrospective.&#xD;
&#xD;
      Immunosuppressive therapy remains the foundation of treatment including single three agents&#xD;
      i.e. methotrexate, oral cyclophosphamide and ciclosporin A. However prospective trials&#xD;
      involving large numbers of patients have not been performed and no molecule has proven&#xD;
      superiority over others.&#xD;
&#xD;
      Invetigators set up at the University Hospital of Rennes, a database of more than 300&#xD;
      patients with LGL leukemia from major French services that support this disease, and&#xD;
      published in 2010 the largest series of patients in the world (n = 229). However, the limited&#xD;
      heterogeneity and retrospective data collected, as all previously released, makes it&#xD;
      difficult the proposal of consensual treatment options. Combining the results of our series&#xD;
      with those of the literature, invetigators estimate that overall response rate and complete&#xD;
      response rate are 55% and 30% with methotrexate, 60% and 50% with cyclophosphamide, and 55%&#xD;
      and less than 20% with ciclosporine A, respectively.&#xD;
&#xD;
      Thus, there are four objective in this study :&#xD;
&#xD;
        1. to compare the respective efficacies of methotrexate and cyclophosphamide when&#xD;
           administered as first-line therapies in patients suffering from T/NK LGL leukemia with&#xD;
           severe neutropenia or neutropenia associated with infections, and/or anemia requiring&#xD;
           transfusions, and/or auto-immune associated disease&#xD;
&#xD;
        2. to evaluate the percentage of patients refractory to methotrexate or cyclophosphamide&#xD;
           for which a second line treatment is efficacious&#xD;
&#xD;
        3. to explore, in case of non-response to the first-line therapy, the efficacy of&#xD;
           ciclosporine A, the comparison being performed with the treatment which was not&#xD;
           administered in the first-line therapy&#xD;
&#xD;
        4. to evaluate the response rate according to the phenotypic subtype of LGL leukemia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 26, 2013</start_date>
  <completion_date type="Anticipated">November 26, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 26, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete response (CR)</measure>
    <time_frame>at Month 4</time_frame>
    <description>The main endpoint will be the hematological CR rate evaluated after 4 months of treatment (binary endpoint). Complete response (CR) is defined as a normalization of clinical examination (disappearance of splenomegaly) and a complete normalization of blood counts (i.e., hemoglobin &gt;12g/dL, platelets &gt;150x109/L, ANC &gt;1.5x109/L), lymphocytosis &lt;4x109/L and circulating LGL in the normal range (&lt;0.3x109/L). The number of LGL will be quantitated on blood smears.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall response rate (ORR)</measure>
    <time_frame>at Month 4, and at Month 8 and Month 12 in non-responders at Month 4</time_frame>
    <description>Hematological overall response rate (ORR) defined as the sum of complete responses and partial responses over the total number of patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response (CR)</measure>
    <time_frame>at Month 8 and Month 12</time_frame>
    <description>Complete response (CR) is defined as a normalization of clinical examination (disappearance of splenomegaly) and a complete normalization of blood counts (i.e., hemoglobin &gt;12g/dL, platelets &gt;150x109/L, ANC &gt;1.5x109/L), lymphocytosis &lt;4x109/L and circulating LGL in the normal range (&lt;0.3x109/L). The number of LGL will be quantitated on blood smears.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematological partial response (PR)</measure>
    <time_frame>at Month 4, Month 8 and Month 12</time_frame>
    <description>Hematological partial response (PR) defined as an improvement in blood counts which do not meet criteria for complete remission (e.g., ANC increasing more than 50% and reaching more than 0.5 but less than 1.5x109/L with non-recurrence of infections, or hemoglobin level increasing more than 2 g/dL from baseline and transfusion requirements stopping without normalization of the hemoglobin level defined as hemoglobin &gt;12g/dL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progressive disease</measure>
    <time_frame>at Month 4, Month 8 and Month 12</time_frame>
    <description>Progressive disease defined as worsening of cytopenia or organomegaly or incidence of infections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-relapse</measure>
    <time_frame>from Month 4 to endpoint (in first-line treatment responders)</time_frame>
    <description>Time-to-relapse (censored variable). Relapse is defined as re-occurrence of either neutropenia or anemia (ANC &lt;1x109/L and/or hemoglobin &lt;10g/dL) or clonal LGL &gt;0.5x109/L in complete responders, or as a return to baseline values of either ANC or hemoglobin in partial responders, at two monthly consecutive blood tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-relapse</measure>
    <time_frame>from Month 8 to endpoint (in second-line treatment responders)</time_frame>
    <description>Time-to-relapse (censored variable). Relapse is defined as re-occurrence of either neutropenia or anemia (ANC &lt;1x109/L and/or hemoglobin &lt;10g/dL) or clonal LGL &gt;0.5x109/L in complete responders, or as a return to baseline values of either ANC or hemoglobin in partial responders, at two monthly consecutive blood tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular remission</measure>
    <time_frame>at Month 4 and Month 12 for hematological complete responders</time_frame>
    <description>Molecular remission defined as the disappearance of the clonal pattern of TCR gamma multiplex rearrangement and Phenotypic remission is defined as :&#xD;
For the T subtype: disappearance of the excess of CD3+/CD8+ cells (or disappearance of the LGL clone according to the specific subtype observed at inclusion);&#xD;
For the NK subtype: disappearance of the excess of CD3-/CD56+ cells (or disappearance of the LGL clone according to the specific subtype observed at inclusion)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events rate</measure>
    <time_frame>Month 2, Month 4, Month 6, Month 8, Month 10, Month 12</time_frame>
    <description>Adverse events rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance</measure>
    <time_frame>Month 2, Month 4, Month 6, Month 8, Month 10, Month 12</time_frame>
    <description>Compliance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relationship between the response to treatment and the phenotypic subtype</measure>
    <time_frame>Day 1</time_frame>
    <description>Identification of a relationship between the response to treatment and the phenotypic subtype characterized by the panel of monoclonal antibodies defined in the ancillary study subsection.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">166</enrollment>
  <condition>Large Granular Lymphocytes Leukemia</condition>
  <arm_group>
    <arm_group_label>METHOTREXATE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In step 1, 55 patients will receive methotrexate 10mg / m² orally once a week, (at split doses of 5 mg/m2 in the morning and 5 mg/m2 at night), that is to say 2 tablets of 2.5 mg at each take&#xD;
In step 2, responders at Month 4 (CR or PR) will be treated during 8 additional months with methotrexate at the same dosage.&#xD;
Non responders at Month 4 will be randomized and treated either by:&#xD;
Cyclophosphamide delivered at 100 mg orally once daily, that is to say 2 tablets of 50 mg at each take between Month 5 and Month 8, decreased to 50 mg orally once daily beyond Month 8 for responders at Month 8;&#xD;
Ciclosporine A delivered at 3 mg/kg per day (at split doses of 1.5 mg/kg in the morning and 1.5 mg/kg at night) orally administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CYCLOPHOSPHAMIDE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In step 1, 55 patients will receive cyclophosphamide 100 mg orally once daily, that is to say 2 tablets of 50 mg at each take.&#xD;
In step 2, responders at Month 4 (CR or PR) will be treated during 8 additional months with cyclophosphamide (at 50 mg orally once daily);&#xD;
Non responders at Month 4 will be randomized and treated either by:&#xD;
Methotrexate administered at 10 mg/m2 orally once a week (at split doses of 5 mg/m2 in the morning and 5 mg/m2 at night), that is to say 2 tablets of 2.5 mg at each take;&#xD;
Ciclosporine A delivered at 3 mg/kg per day (at split doses of 1.5 mg/kg in the morning and 1.5 mg/kg at night) orally administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>methotrexate 10mg / m² orally once a week, (at split doses of 5 mg/m2 in the morning and 5 mg/m2 at night), that is to say 2 tablets of 2.5 mg at each take, during 4 months.</description>
    <arm_group_label>METHOTREXATE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>cyclophosphamide 100 mg orally once daily, that is to say 2 tablets of 50 mg at each take, during 4 months.</description>
    <arm_group_label>CYCLOPHOSPHAMIDE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Common criteria of LGL leukemia: the diagnosis is based on a chronic LGL peripheral&#xD;
             blood expansion (&gt;0.5x109/L), usually lasting more than 6 months&#xD;
&#xD;
          -  Specific criteria for T-LGL leukemia or NK-LGL lymphocytosis or chronic NK-LGL&#xD;
             leukemia:&#xD;
&#xD;
               -  Specific criteria for T-LGL leukemia:&#xD;
&#xD;
          -  Expression of LGL surface markers compatible with an activated T-cell (commonly&#xD;
             alpha-beta+/CD3+/CD8+/CD57+ and/or CD16+) phenotype or gamma-delta+ T cells;&#xD;
&#xD;
          -  Clonal rearrangement of TCRγ gene using PCR or specific and clonal Vβ expression using&#xD;
             FCM.&#xD;
&#xD;
               -  Specific criteria for NK-LGL lymphocytosis or chronic NK LGL leukemia:&#xD;
&#xD;
          -  Expression of LGL surface markers compatible with a NK cell (commonly CD3-/CD8+/CD16+&#xD;
             and/or CD16+/CD56+) phenotype;&#xD;
&#xD;
          -  CD56+ or CD16+ NK cells greater than 0.75x109/L;&#xD;
&#xD;
          -  The term of chronic NK-LGL lymphocytosis is used for patients with chronic illness&#xD;
             (NB: patients with massive tissue LGL infiltration of the spleen, liver and bone&#xD;
             marrow and presenting aggressive clinical behavior are considered as having aggressive&#xD;
             NK-LGL leukemia and should not be included).&#xD;
&#xD;
          -  Age above 18 years&#xD;
&#xD;
          -  ECOG performance status of 0-2&#xD;
&#xD;
          -  Life expectancy of at least 1 year&#xD;
&#xD;
          -  Lack of previous treatment (except with G-CSF or transfusions)&#xD;
&#xD;
          -  At least one indication of treatment:&#xD;
&#xD;
               -  Isolated severe neutropenia (ANC &lt;0.5x109/L) or neutropenia (ANC &lt;1.5x109/L) with&#xD;
                  two or more infections requiring antibiotics;&#xD;
&#xD;
               -  Anemia (whatever the underlying mechanism: pure red cell aplasia or marrow&#xD;
                  infiltration) requiring transfusions greater than 2 units for two months prior to&#xD;
                  inclusion, or symptomatic anemia (hemoglobin &lt;10g/dl) with impairment of the&#xD;
                  quality of life;&#xD;
&#xD;
               -  Associated complications such as systemic diseases or auto-immune diseases (i.e.&#xD;
                  recurrent uveitis, cutaneous vasculitis, autoimmune hemolytic anemia, idiopathic&#xD;
                  thrombocytopenic purpura, rheumatoid arthritis resistant to steroids and/or&#xD;
                  immunomodulator agents (colchicin, disulone, hydrochloroquine)) and justifying a&#xD;
                  treatment with methotrexate or cyclophosphamide&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to understand or to follow study procedures&#xD;
&#xD;
          -  Prior or concurrent malignancy within the past 5 years except inactive nonmelanomatous&#xD;
             skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  Other serious medical illnesses, such as hepatic, renal, cardiac, pulmonary,&#xD;
             neurologic, or metabolic disease that would preclude the patient's ability to tolerate&#xD;
             methotrexate, cyclophosphamide, or ciclosporine A&#xD;
&#xD;
          -  Reactive LGL lymphocytosis (i.e. after viral infection)&#xD;
&#xD;
          -  ALAT/ASAT or alkalin phosphatases &gt;3 times normal values&#xD;
&#xD;
          -  Creatinine clairance &lt;50 ml/min&#xD;
&#xD;
          -  Serologic evidence of HIV, hepatitis C or hepatitis B infection&#xD;
&#xD;
          -  Non effective contraception&#xD;
&#xD;
          -  Positive pregnancy test&#xD;
&#xD;
          -  Nursing woman&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Thierry Lamy, PUPH</last_name>
    <phone>02 99 28 42 91</phone>
    <phone_ext>+33</phone_ext>
    <email>thierry.lamy@chu-rennes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Sud</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Pierre MAROLLEAU, MD</last_name>
      <phone>03 22 45 59 20</phone>
      <phone_ext>+33</phone_ext>
      <email>marolleau.jean-pierre@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Pierre MAROLLEAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malgorzata truchand-Graczyk, MD</last_name>
      <phone>02 41 35 45 24</phone>
      <phone_ext>+33</phone_ext>
      <email>MaTruchan@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>Malgorazata Truchand-Graczyk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Intern medecine Service - CH Antibes-Juan-les-Pins</name>
      <address>
        <city>Antibes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel RE, MD</last_name>
      <phone>04 97 24 77 46</phone>
      <phone_ext>+33</phone_ext>
      <email>daniel.re@ch-antibes.fr</email>
    </contact>
    <investigator>
      <last_name>Daniel RE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Service - CH Avignon</name>
      <address>
        <city>Avignon</city>
        <zip>84902</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hacène ZERAZHI, MD</last_name>
      <phone>04 32 75 93 93</phone>
      <phone_ext>+33</phone_ext>
      <email>hzerazhi@ch-avignon.fr</email>
    </contact>
    <investigator>
      <last_name>Zerazhi Hacène, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Service - CH de la cote basque</name>
      <address>
        <city>Bayonne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Banos, MD</last_name>
      <phone>05 59 44 38 32</phone>
      <phone_ext>+33</phone_ext>
      <email>abanos@ch-cotebasque.fr</email>
    </contact>
    <investigator>
      <last_name>Anne Banos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>hematology service - CH Beauvais</name>
      <address>
        <city>Beauvais</city>
        <zip>60021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mustapha Ghomari, MD</last_name>
      <phone>03 44 11 23 90</phone>
      <phone_ext>+33</phone_ext>
      <email>kamel.ghomari@ch-beauvais.fr</email>
    </contact>
    <investigator>
      <last_name>Mustapha Ghomari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Service - CH Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annie BRION, MD</last_name>
      <phone>03 81 66 82 32</phone>
      <phone_ext>+33</phone_ext>
      <email>abrion@chu-besancon.fr</email>
    </contact>
    <investigator>
      <last_name>Annie BRION, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Service - CH Beziers</name>
      <address>
        <city>Beziers</city>
        <zip>34500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain SAAD, MD</last_name>
      <phone>04 67 35 70 63</phone>
      <phone_ext>+33</phone_ext>
      <email>alain.saad@ch-beziers.fr</email>
    </contact>
    <investigator>
      <last_name>Alain SAAD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Unit - HOpital Avicienne</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence Cymbalista, MD</last_name>
      <phone>01 48 95 56 40</phone>
      <phone_ext>+33</phone_ext>
      <email>florence.cymbalista@avc.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Florence Cymbalista, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Service - CH Docteur Duchenne</name>
      <address>
        <city>Boulogne sur Mer</city>
        <zip>62321</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bertrand POLLET, MD</last_name>
      <phone>03 21 99 82 02</phone>
      <phone_ext>+33</phone_ext>
      <email>b.pollet@ch-boulogne.fr</email>
    </contact>
    <investigator>
      <last_name>Bertrand POLLET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Service - CH de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hussam SAAD, MD</last_name>
      <phone>02 98 22 34 21</phone>
      <phone_ext>+33</phone_ext>
      <email>hussam.saad@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>hussam SAAD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Service - CH François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Pierre VILQUE, MD</last_name>
      <phone>02 31 45 50 12</phone>
      <phone_ext>+33</phone_ext>
      <email>jp.vilque@baclesse.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Pierre VILQUE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Achille AOUBA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>hematology Service - CH Louis Pasteur</name>
      <address>
        <city>Chartres</city>
        <zip>28018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Michel MICLEA, MD</last_name>
      <phone>02 37 30 30 77</phone>
      <phone_ext>+33</phone_ext>
      <email>jmmiclea@ch-chartres.fr</email>
    </contact>
    <investigator>
      <last_name>Jean Michel MICLEA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Cholet</name>
      <address>
        <city>Cholet</city>
        <zip>49300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Bescond, MD</last_name>
      <phone>02 41 49 84 91</phone>
      <phone_ext>+33</phone_ext>
      <email>charles.bescond@ch-cholet.fr</email>
    </contact>
    <investigator>
      <last_name>Charles Bescond, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Inter-Armées Percy</name>
      <address>
        <city>Clamart</city>
        <zip>92141</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Valère MALFUSON, MD</last_name>
      <phone>01 41 46 63 01</phone>
      <phone_ext>+33</phone_ext>
    </contact>
    <investigator>
      <last_name>Jean-Valère MALFUSON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>hematology Service - CHU Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Tournilhac, MD</last_name>
      <phone>04 73 75 00 65</phone>
      <phone_ext>+33</phone_ext>
      <email>otournilhac@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Joel Fleury, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier Tournilhac, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Service - Civils hospital</name>
      <address>
        <city>Colmar</city>
        <zip>68024</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammed Belkaid, MD</last_name>
      <phone>03 89 12 43 29</phone>
      <phone_ext>+33</phone_ext>
      <email>mohammed.belkaid@ch-colmar.fr</email>
    </contact>
    <investigator>
      <last_name>Mohammed BELKAID, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Service CHSF</name>
      <address>
        <city>Corbeil Essonnes</city>
        <zip>91110</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Célia SALANOUBAT, MD</last_name>
      <phone>01 60 90 31 78</phone>
      <phone_ext>+33</phone_ext>
      <email>celia.salanoubat@ch-sud-francilien.fr</email>
    </contact>
    <investigator>
      <last_name>Célia SALANOUBAT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Henri Mondor Lymphoid Hemopathy Unit</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jehan DUPUIS, MD</last_name>
      <phone>01 49 81 41 74</phone>
      <phone_ext>+33</phone_ext>
      <email>jehan.dupuis@hmn.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Jehan DUPUIS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc MICHEL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Dijon Hematology Unit</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuelle FERRANT, MD</last_name>
      <phone>03 80 29 50 41</phone>
      <phone_ext>+33</phone_ext>
      <email>emmanuelle.ferrant@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Emmanuelle FERRNAT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Unit CH Michalon</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lysiane MOLINA, MD</last_name>
      <phone>04 76 76 76 69</phone>
      <phone_ext>+33</phone_ext>
      <email>lmolina@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Lysiane Molina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Unit CHD Vendée</name>
      <address>
        <city>La Roche sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mourad TIAB, MD</last_name>
      <phone>02 51 44 61 73</phone>
      <phone_ext>+33</phone_ext>
      <email>mourad.tiab@chd.vendee.fr</email>
    </contact>
    <investigator>
      <last_name>Mourad TIAB, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Unit CH LE MANS</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kamel Laribi, MD</last_name>
      <phone>02 43 43 29 59</phone>
      <phone_ext>+33</phone_ext>
      <email>klaribi@ch-lemans.fr</email>
    </contact>
    <investigator>
      <last_name>Kamel Laribi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Robert Boulin</name>
      <address>
        <city>Libourne</city>
        <zip>33500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gaëlle Laboure, MD</last_name>
      <phone>05 57 55 26 17</phone>
      <phone_ext>+33</phone_ext>
      <email>gaelle.laboure@ch-libourne.fr</email>
    </contact>
    <investigator>
      <last_name>Gaëlle Laboure, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Unit CHRU Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louis TERRIOU, MD</last_name>
      <phone>03 20 44 42 90</phone>
      <phone_ext>+33</phone_ext>
      <email>louis.terriou@free.fr</email>
    </contact>
    <investigator>
      <last_name>Louis TERRIOU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Unit CHU Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnaud Jaccard, MD</last_name>
      <phone>05 55 05 66 51</phone>
      <phone_ext>+33</phone_ext>
      <email>arnaud.jaccard@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>Arnaud Jaccard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Bretagne Sud</name>
      <address>
        <city>Lorient</city>
        <zip>56322</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe MOREAU, MD</last_name>
    </contact>
    <investigator>
      <last_name>Philippe MOREAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Unit CHU La Conception</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regis Costello, MD</last_name>
      <phone>04 91 38 41 50</phone>
      <phone_ext>+33</phone_ext>
      <email>regis.costello@free.fr</email>
    </contact>
    <investigator>
      <last_name>Regis Costello, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Unit - Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thérèse Aurran-Schleinitz, MD</last_name>
      <phone>04 91 22 38 66</phone>
      <phone_ext>+33</phone_ext>
      <email>aurrant@marseille.fnclcc.fr</email>
    </contact>
    <investigator>
      <last_name>Thérèse Aurran-Schleinitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jérome REY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Unit CH Meaux</name>
      <address>
        <city>Meaux</city>
        <zip>77100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wajed Abarah, MD</last_name>
      <phone>01 64 35 38 75</phone>
      <phone_ext>+33</phone_ext>
      <email>w-abarah@ch-meaux.fr</email>
    </contact>
    <investigator>
      <last_name>Wajed Abarah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Unit CH Notre Dame Bon Secours</name>
      <address>
        <city>Metz</city>
        <zip>57000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe CARASSOU, MD</last_name>
      <phone>03 87 55 32 32</phone>
      <phone_ext>+33</phone_ext>
      <email>p.carassou@chr-metz-thionville.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe CARASSOU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematogy Unit CHU ST ELOI</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume CARTRON, MD</last_name>
      <phone>04 67 33 83 62</phone>
      <phone_ext>+33</phone_ext>
      <email>g-cartron@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Guillaume CARTRON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Unit CH E.MULLER</name>
      <address>
        <city>Mulhouse</city>
        <zip>68070</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard DRENOU, MD</last_name>
      <phone>03 89 64 77 85</phone>
      <phone_ext>+33</phone_ext>
      <email>drenoub@ch-mulhouse.fr</email>
    </contact>
    <investigator>
      <last_name>Bernard DRENOU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Internal Medicine - CHU Hotel Dieu</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed HAMIDOU, MD</last_name>
      <email>mohamed.hamidou@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncology Unit CH Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel RE, MD</last_name>
      <phone>04 92 03 16 18</phone>
      <phone_ext>+33</phone_ext>
      <email>daniel.re@ch-antibes.fr</email>
    </contact>
    <investigator>
      <last_name>Daniel RE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>hematology Unit CHU Caremeau</name>
      <address>
        <city>Nimes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric JOURDAN, MD</last_name>
      <phone>04 66 68 32 31</phone>
      <phone_ext>+33</phone_ext>
      <email>eric.jourdan@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Eric Jourdan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Unit - CHR Orleans</name>
      <address>
        <city>Orleans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magda ALEXIS, MD</last_name>
      <phone>02 38 22 95 47</phone>
      <phone_ext>+33</phone_ext>
      <email>magda.alexis@chr-orleans.fr</email>
    </contact>
    <investigator>
      <last_name>Magda ALEXIS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Service - Hopital La Pitié Salpetrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Véronique LEBLOND, MD</last_name>
      <phone>01 42 16 28 24</phone>
      <phone_ext>+33</phone_ext>
      <email>veronique.leblond@psl.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Véronique LEBLOND, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sylvain CHOQUET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Unit - Hopital Hotel Dieu</name>
      <address>
        <city>Paris</city>
        <zip>75181</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François DREYFUS, MD</last_name>
      <phone>01 42 34 87 65</phone>
      <phone_ext>+33</phone_ext>
      <email>francois.dreyfus@cch.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>François DREYFUS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Unit - Hopital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne VEKHOFF, MD</last_name>
      <phone>01 49 28 34 29</phone>
      <phone_ext>+33</phone_ext>
      <email>anne-vekhoff@sat.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Anne VEKHOFF, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP Hôpital Necker - Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Hermine, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Richard Delarue, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hematology Unit - Hopital Saint Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marion MALPHETTES, MD</last_name>
      <phone>01 42 49 92 97</phone>
      <phone_ext>+33</phone_ext>
    </contact>
    <investigator>
      <last_name>Marion MALPHETTES, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Unit Hopital Saint Jean</name>
      <address>
        <city>Perpignan</city>
        <zip>66000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence SANHES, MD</last_name>
      <phone>04 68 61 64 48</phone>
      <phone_ext>+33</phone_ext>
      <email>laurence.sanhes@ch-perpignan.fr</email>
    </contact>
    <investigator>
      <last_name>Laurence SANHES, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Service- CH Haut Leveque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Sarah Dilhuydy, MD</last_name>
      <phone>05 57 65 65 11</phone>
      <phone_ext>+33</phone_ext>
      <email>marie-sarah.dilhuydy@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Marie-Sarah DILHUYDY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-François VIALLARD, PUPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Unit CH LYON SUD</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Lazareth, MD</last_name>
      <phone>04 78 86 43 09</phone>
      <phone_ext>+33</phone_ext>
      <email>anne.lazareth@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Anne Lazareth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Unit CHU La Miletrie</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cécile TOMOWIAC, MD</last_name>
      <phone>05 49 44 43 07</phone>
      <phone_ext>+33</phone_ext>
      <email>c.tomowiac@chu-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>Cécile TOMOWIAC, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Unit CH René DUBOS</name>
      <address>
        <city>Pontoise</city>
        <zip>95000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hugo GONZALEZ, MD</last_name>
      <phone>01 30 75 47 35</phone>
      <phone_ext>+33</phone_ext>
      <email>hugo.gonzalez@ch-pontoise.fr</email>
    </contact>
    <investigator>
      <last_name>Hugo GONZALEZ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Annecy - Hematology Service</name>
      <address>
        <city>Pringy</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédérique orsini-piocelle, MD</last_name>
      <phone>04 50 63 66 08</phone>
      <phone_ext>+33</phone_ext>
      <email>forsinipiocelle@ch-annecy.fr</email>
    </contact>
    <investigator>
      <last_name>Frédérique Orsini-Piocelle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Unit- Hopital Robert Debré</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain DELMER, MD</last_name>
      <phone>03 26 78 36 44</phone>
      <phone_ext>+33</phone_ext>
      <email>adelmer@chu-reims.fr</email>
    </contact>
    <investigator>
      <last_name>Alain DELMER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Service - CHU of Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry Lamy, PUPH</last_name>
      <phone>02 99 28 42 91</phone>
      <phone_ext>+33</phone_ext>
      <email>thierry.lamy@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Thierry Lamy, PUPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Unit - CH Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane LEPETRE, MD</last_name>
      <phone>02 32 08 22 23</phone>
      <phone_ext>+33</phone_ext>
      <email>stelep@rouen.fnclcc.fr</email>
    </contact>
    <investigator>
      <last_name>Stéphane LEPETRE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Unit - Institut de cancérologie de la Loire</name>
      <address>
        <city>Saint Priest en Jarez</city>
        <zip>60008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karine AUGEUL-MEUNIER, MD</last_name>
      <phone>04 77 91 70 60</phone>
      <phone_ext>+33</phone_ext>
      <email>karine.augeul-meunier@icloire.fr</email>
    </contact>
    <investigator>
      <last_name>Karine AUGEUL-MEUNIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Saint Quentin Oncohematology</name>
      <address>
        <city>Saint Quentin</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reda GARIDI, MD</last_name>
      <phone>03 23 06 78 61</phone>
      <phone_ext>+33</phone_ext>
      <email>r.garidi@ch-stquentin.fr</email>
    </contact>
    <investigator>
      <last_name>Reda GARIDI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Yves Lefoll</name>
      <address>
        <city>Saint-Brieuc</city>
        <zip>22027</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent LAUNAY, MD</last_name>
    </contact>
    <investigator>
      <last_name>Vincent LAUNAY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Unit CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loic YSEBAERT, MD</last_name>
      <phone>05 61 77 76 68</phone>
      <phone_ext>+33</phone_ext>
      <email>ysebaert.l@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Loic YSEBEART, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel ADOUE, PUPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Unit CHU Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline DARTIGAS, MD</last_name>
      <phone>02 47 47 37 12</phone>
      <phone_ext>+33</phone_ext>
      <email>c.dartigeas@chu-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Caroline DARTIGAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Unit Hopitaux de Brabois</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre FEUGIER, MD</last_name>
      <phone>03 83 15 32 82</phone>
      <phone_ext>+33</phone_ext>
      <email>p.feugier@chu-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre FEUGIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Intern Medecine Unit CHBA</name>
      <address>
        <city>Vannes</city>
        <zip>56017</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal GODMER, MD</last_name>
      <phone>02 97 01 41 45</phone>
      <phone_ext>+33</phone_ext>
      <email>pascal.godmer@ch-bretagne-atlantique.fr</email>
    </contact>
    <investigator>
      <last_name>Pascal GODMER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital André Mignot Centre Hospitalier de Versailles</name>
      <address>
        <city>Versailles</city>
        <zip>78157</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milena Kohn, MD</last_name>
      <email>mikohn@ch-versailles.fr</email>
    </contact>
    <investigator>
      <last_name>Milena Kohn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 22, 2013</study_first_submitted>
  <study_first_submitted_qc>November 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2013</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>large granular lymphocytes leukemia</keyword>
  <keyword>immunosuppressive drugs</keyword>
  <keyword>methotrexate</keyword>
  <keyword>cyclophosphamide</keyword>
  <keyword>efficiency</keyword>
  <keyword>phase II randomized controlled trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Large Granular Lymphocytic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

